Abstract:Lamin A/C gene ( LMNA ) mutations contribute to severe striated muscle laminopathies, affecting cardiac and skeletal muscles, with limited treatment options. In this study, we delve into the investigations of five distinct LMNA mutations, including three novel variants and two pathogenic variants identified in patients with muscular laminopathy. Our approach employs zebrafish models to comprehensively study these variants. Transgenic zebrafish expressing wild-type LMNA and each mutation undergo extensive morphological profiling, swimming behavior assessments, muscle endurance evaluations, heartbeat measurement, and histopathological analysis of skeletal muscles. Additionally, these models serve as platform for focused drug screening. We explore the transcriptomic landscape through qPCR and RNAseq to unveil altered gene expression profiles in muscle tissues. Larvae of LMNA (L35P), LMNA (E358K), and LMNA (R453W) transgenic fish exhibit reduced swim speed compared to LMNA (WT) measured by DanioVision. All LMNA transgenic adult fish exhibit reduced swim speed compared to LMNA (WT) in T-maze. Moreover, all LMNA transgenic adult fish, except LMNA (E358K), display weaker muscle endurance than LMNA (WT) measured by swimming tunnel. Histochemical staining reveals decreased fiber size in all LMNA mutations transgenic fish, excluding LMNA (WT) fish. Interestingly, LMNA (A539V) and LMNA (E358K) exhibited elevated heartbeats. We recognize potential limitations with transgene overexpression and conducted association calculations to explore its effects on zebrafish phenotypes. Our results suggest lamin A/C overexpression may not directly impact mutant phenotypes, such as impaired swim speed, increased heart rates, or decreased muscle fiber diameter. Utilizing LMNA zebrafish models for drug screening, we identify l -carnitine treatment rescuing muscle endurance in LMNA (L35P) and creatine treatment reversing muscle endurance in LMNA (R453W) zebrafish models. Creatine activates AMPK and mTOR pathways, improving muscle endurance and swim speed in LMNA (R453W) fish. Transcriptomic profiling reveals upstream regulators and affected genes contributing to motor dysfunction, cardiac anomalies, and ion flux dysregulation in LMNA mutant transgenic fish. These findings faithfully mimic clinical manifestations of muscular laminopathies, including dysmorphism, early mortality, decreased fiber size, and muscle dysfunction in zebrafish. Furthermore, our drug screening results suggest l -carnitine and creatine treatments as potential rescuers of muscle endurance in LMNA (L35P) and LMNA (R453W) zebrafish models. Our study offers valuable insights into the future development of potential treatments for LMNA -related muscular laminopathy.

LMNA p.Arg624His Variant Reduces Lamin Expression at mRNA Level: Elucidating Molecular Pathways toward Cardiac Involvement in Laminopathies

LMNA p.Arg624His missense variant reduces lamin expression at mRNA level: elucidating molecular pathways toward cardiac involvement in laminopathies

A new laminopathy caused by an Arg133/Leu mutation in lamin A/C and the effects thereof on adipocyte differentiation and the transcriptome.

Global Proteomic Analysis Reveals Alterations in Differentially Expressed Proteins between Cardiopathic Lamin A/C Mutations

Clinical and Functional Characterization of a Novel Mutation in Lamin A/C Gene in a Multigenerational Family with Arrhythmogenic Cardiac Laminopathy

An alpha-helix variant p.Arg156Pro in LMNA as a cause of hereditary dilated cardiomyopathy: genetics and bioinfomatics exploration

Lamin A/C-dependent chromatin architecture safeguards naïve pluripotency to prevent aberrant cardiovascular cell fate and function

The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope

A lamin A/C variant causing striated muscle disease provides insights into filament organization

LMNA -Related Dilated Cardiomyopathy: Single-Cell Transcriptomics during Patient-derived iPSC Differentiation Support Cell type and Lineage-specific Dysregulation of Gene Expression and Development for Cardiomyocytes and Epicardium-Derived Cells with Lamin A/C Haploinsufficiency

LMNA-Related Dilated Cardiomyopathy: Single-Cell Transcriptomics during Patient-Derived iPSC Differentiation Support Cell Type and Lineage-Specific Dysregulation of Gene Expression and Development for Cardiomyocytes and Epicardium-Derived Cells with Lamin A/C Haploinsufficiency

Abstract MP175: Disruption of the Genome Architecture at the PRRX1 Locus is Associated With the Pathogenesis of LMNA -related Dilated Cardiomyopathy

Creatine and l-carnitine attenuate muscular laminopathy in the LMNA mutation transgenic zebrafish

In Silico and In Vivo Analysis of Amino Acid Substitutions That Cause Laminopathies

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

A Novel Deletion Mutation Accompanied by a Point Mutation in Lamin A/C Gene: Screened from a Dilated Cardiomyopathy Family.

Lamin A K97E leads to NF‐κB‐mediated dysfunction of inflammatory responses in dilated cardiomyopathy

The H222P-Lamin mutation induces heart failure via impaired mitochondrial calcium uptake in human cardiac laminopathy

Next-generation sequencing identifies a novel heterozygous I229T mutation on LMNA associated with familial cardiac conduction disease.

Juvenile‐onset Generalized Lipodystrophy Due to a Novel Heterozygous Missense LMNA Mutation Affecting Lamin C

LMNA-related Muscular Dystrophy Involving Myoblast Proliferation and Apoptosis Through the FOXO1/GADD45A Pathway.